Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing‐Impaired Patients With Type 2 Diabetes
Pharmacology Research & Perspectives · 2026
DOI: 10.1002/prp2.70316 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pharmacology Research & Perspectives, 2026. Verfasst von Francesco Martines und 8 weiteren Autor:innen. Beteiligte Einrichtung: Section of Audiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Auditory Threshold, Hearing Loss, Sensorineural. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Research Fund - FFR 2025.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM) has increasingly been identified as a risk factor for sensorineural hearing loss, whereas the association between different antidiabetic therapies and hearing thresholds remains poorly characterized. This retrospective observational study evaluated 240 patients with T2DM and 105 normoglycemic controls who underwent standardized pure‐tone audiometry at the Audiology Section of the University of Palermo between February 2025 and January 2026. Hearing thresholds were measured using the pure tone average (PTA‐mean) at 0.5, 1, 2, and 4 kHz, corresponding to speech‐relevant frequencies. Multivariable analysis of covariance, adjusted for age, sex, body mass index, and smoking status, showed that subjects with T2DM had significantly higher PTA‐mean values compared to controls (64.4 ± 17.1 dB vs. 56.4 ± 14.8 dB; p = 0.007), indicating worse hearing thresholds. Among specific antidiabetic treatments, GLP‐1RAs, metformin, and pioglitazone were associated with lower PTA‐mean values. Furthermore, pharmacological class analysis showed that GLP‐1 receptor agonists and biguanides were associated with more favorable hearing thresholds. These findings suggest that antidiabetic pharmacotherapy may show class‐specific associations with auditory function, supporting the need for prospective studies to evaluate whether hearing outcomes should be considered in the broader management of diabetes‐related comorbidities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Audiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy.
- Department of Health Promotion Sciences, Maternal and Child Care, Internal Medicine and Medical Specialties "Giuseppe D'Alessandro", University of Palermo, Palermo, Italy.
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy.
ORCID-Profile: Ginevra Malta, Stella Cascioferro, Gianluca Lavanco, Fulvio Plescia
Förderung
- University Research Fund - FFR 2025
Zitieren
APA
Martines, F., Salvago, P., Vaccaro, F., Vaccaro, D., Malta, G., Plescia, F., Cascioferro, S., Lavanco, G., & Plescia, F. (2026). Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing‐Impaired Patients With Type 2 Diabetes. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70316
Vancouver
Martines F, Salvago P, Vaccaro F, Vaccaro D, Malta G, Plescia F, et al. Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing‐Impaired Patients With Type 2 Diabetes. Pharmacology Research & Perspectives. 2026. doi:10.1002/prp2.70316
BibTeX
@article{Martines2026,
author = {Martines, Francesco and Salvago, Pietro and Vaccaro, Francesca and Vaccaro, Davide and Malta, Ginevra and Plescia, Fabiana and Cascioferro, Stella and Lavanco, Gianluca and Plescia, Fulvio},
title = {Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing‐Impaired Patients With Type 2 Diabetes},
journal = {Pharmacology Research & Perspectives},
year = {2026},
doi = {10.1002/prp2.70316}
}
EUVIMED